Volume : 12, Issue : 10, October – 2025
Title:
FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF TERBUTALINE FLOATING TABLETS
Authors :
Katroth Jithender*, Chandrasekhara Rao Baru, Sushma Desai
Abstract :
The present study outlines a systematic approach for designing and development of Terbutaline floating tablets to enhance the bioavailability and therapeutic efficacy of the drug. Floating tablets of Terbutaline have shown sustained release there by proper duration of action at a particular site and are designed to prolong the gastric residence time after oral administration. Different formulations were formulated by using direct compression method. A floating drug delivery system (FDDS) was developed by using sodium bicarbonate as gas-forming agent and HPMC E5, Eudragit RLPO and Sodium carboxy methylcellulose as polymers. The prepared tablets were evaluated in terms of their physical characteristics, pre-compression parameters, in vitro release and buoyancy lag time. The results of the in vitro release studies showed that the optimized formulation (T7) could sustain drug release for 12 hrs by using Sodium carboxy methylcellulose in the concentration of 5mg. The in vitro drug release followed zero order kinetics.
Key words: Terbutaline, HPMC E5, Eudragit RLPO and Sodium carboxy methylcellulose and Floating tablets
Cite This Article:
Please cite this article in press Katroth Jithender et al., Formulation Development And In Vitro Evaluation Of Terbutaline Floating Tablets , Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv, 2006; 3(2): 217- 33.
2. 2. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop. J Pharm Res, 2008; 7(3): 1055-66.
3. Rouge N, Allemann E, Gex-Fabry M, Balant L, Cole ET, Buri P, Doelker E. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high density multipleunit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Acta Helbetiae, 1998; 73: 81-7.
4. Streubel A, Siepmann J, Bodmeier R. Multiple unit Gastroretentive drug delivery: a new preparation method for low density microparticles. J Microencapsul, 2003; 20: 329-47.
5. Goole J, Vanderbist F, Aruighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. Int J Pharm, 2007; 334: 35-41.
6. Shrma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm, 2006; 313: 150-58.
7. Santus G, Lazzarini G, Bottoni G, Sandefer EP, Page RC, Doll WJ, Ryo UY, Digenis GA. An in vitro- in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm 1997; 44: 39-52.
8. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90: 143-62.
9. Deshpande AA, Shah N, Rhodes CT, Malik W. Development of a novel controlled-release system for gastric retention. Pharm Res 1997; 14: 815-19.
10. Park K. Enzyme-digestible swelling as platforms for longterm oral drug delivery: synthesis and characterization. Biomaterials 1988; 9: 435.